Sano Genetics

Sano Genetics provides an online platform that combines genetic testing, recruitment, and long-term patient-clinician engagement to assist in clinical trials. The platform helps to connect patients across four countries, UK, US, Australia, and Canada, with pharmaceutical and biotechnology companies conducting clinical trials through advertising initiatives in social media and via healthcare providers. Post-patient recruitment, the platform additionally assists with patient communication, facilitating genetic and other biomarker testing, returning results, and supporting patients with genetic counseling.

In January 2024, the company noted it had recorded a 5x YoY growth in ARR in 2023 and doubled its staff to 62.

Key customers and partnerships

As of January 2024, the company noted that it has initiated partnerships with four of the top 20 pharmaceutical companies.

In May 2022, the company partnered with PrecisionLife to accelerate understanding of long Covid-19 and help identify new treatments. Through the partnership, Sano Genetics’ data from 3,000 UK adults suffering from long Covid-19 symptoms were expected to be analyzed using PrecisionLife’s proprietary combinatorial analytics platform to identify risk-factors and potential drug targets.

Funding and financials

In January 2024, Sano raised USD 11.4 million in a funding round led by Plural, with participation from existing investors. The funding was set aside to cater to the growing demand for Sano Genetics' products, incorporate AI more extensively, and expand its footprint in additional countries.